Palatin Technologies (NYSEAMERICAN:PTN) Issues Quarterly Earnings Results, Misses Expectations By $0.58 EPS

Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.58), reports. The business had revenue of $0.36 million for the quarter, compared to analysts’ expectations of $1.79 million.

Palatin Technologies Price Performance

Shares of PTN traded down $0.01 during midday trading on Wednesday, hitting $5.35. The company had a trading volume of 5,466 shares, compared to its average volume of 35,372. The company’s 50 day moving average price is $7.93 and its 200 day moving average price is $13.39. Palatin Technologies has a 52 week low of $4.51 and a 52 week high of $31.00.

About Palatin Technologies

(Get Free Report)

Palatin Technologies is a biopharmaceutical company focused on developing medicines that target melanocortin receptors, which are involved in processes such as inflammation, immune response and appetite regulation. Its research has included peptide-based treatments for inflammatory and other medical conditions. The company is best known for developing bremelanotide, marketed as Vyleesi, which the U.S. Food and Drug Administration approved in 2019 to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.

See Also

Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.